Leflunomide Zentiva

Leflunomide, the active ingredient in Leflunomide Zentiva, is a disease-modifying antirheumatic drug (DMARD) presented as a tablet for oral use. It is prescribed to manage rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce inflammation and prevent joint damage, and is often used as part of a disease‑modifying treatment regimen.

GNH USA supplies Leflunomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Leflunomide is a disease-modifying antirheumatic drug that targets inflammatory pathways in rheumatic conditions.

Rheumatoid arthritis: reduces disease activity, slows joint erosion, and improves functional ability. Psoriatic arthritis: alleviates joint pain and skin involvement while limiting structural damage. Moderate to severe rheumatoid arthritis: used when conventional therapy is insufficient to control symptoms.

Leflunomide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Diarrhea - Nausea or abdominal discomfort - Alopecia or hair thinning - Rash or pruritus - Elevated liver enzymes - Hypertension

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Bone marrow suppression leading to anemia or leukopenia - Pulmonary toxicity, including interstitial lung disease - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Teratogenic effects and fetal malformations

When prescribing Leflunomide, clinicians should observe several safety precautions to minimize risk.

Liver function monitoring: obtain baseline hepatic enzymes and repeat periodically. Hematologic monitoring: perform regular complete blood counts to detect cytopenias. Pregnancy contraindication: avoid use in women who are pregnant or may become pregnant. Concomitant immunosuppressants: use caution with other agents that suppress bone marrow. Infection risk: defer therapy in patients with active serious infections. Store at room temperature: keep in the original container, protect from moisture and light.

Leflunomide interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Methotrexate: combined use increases risk of hepatotoxicity and bone‑marrow suppression. - Warfarin: Leflunomide may potentiate anticoagulant effects, raising bleeding risk. - Rifampin: strong enzyme induction reduces Leflunomide plasma concentrations, diminishing efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: concurrent use can heighten liver enzyme elevations. - Azathioprine: may enhance bone‑marrow suppression. - Statins: combined therapy may increase hepatic enzyme abnormalities.